ARMP Quote, Financials, Valuation and Earnings

Innoviva has a net margin of -- compared to Armata Pharmaceuticals's net margin of 22.15%. Armata Pharmaceuticals's return on equity of -- beat Innoviva's return on equity of 3.44%.

Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 503.45%. On the other hand Innoviva has an analysts' consensus of $19.00 which suggests that it could grow by 5.67%. Given that Armata Pharmaceuticals has higher upside potential than Innoviva, analysts believe Armata Pharmaceuticals is more attractive than Innoviva.

Armata Pharmaceuticals has a beta of 0.914, which suggesting that the stock is 8.595% less volatile than S&P 500. In comparison Innoviva has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.553%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Innoviva pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Innoviva quarterly revenues of $91.8M. Armata Pharmaceuticals's net income of $2.6M is lower than Innoviva's net income of $20.3M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Innoviva's PE ratio is 94.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 420.46x versus 3.98x for Innoviva. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Armata Pharmaceuticals's net margin of 35.65%. Armata Pharmaceuticals's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 503.45%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 453.44%. Given that Armata Pharmaceuticals has higher upside potential than Protalix BioTherapeutics, analysts believe Armata Pharmaceuticals is more attractive than Protalix BioTherapeutics.

Armata Pharmaceuticals has a beta of 0.914, which suggesting that the stock is 8.595% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Armata Pharmaceuticals's net income of $2.6M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 87.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 420.46x versus 4.07x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Armata Pharmaceuticals's net margin of -18.58%. Armata Pharmaceuticals's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 503.45%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Armata Pharmaceuticals has higher upside potential than Retractable Technologies, analysts believe Armata Pharmaceuticals is more attractive than Retractable Technologies.

Armata Pharmaceuticals has a beta of 0.914, which suggesting that the stock is 8.595% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Armata Pharmaceuticals's net income of $2.6M is higher than Retractable Technologies's net income of -$1.9M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 420.46x versus 0.64x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -- compared to Armata Pharmaceuticals's net margin of -118.53%. Armata Pharmaceuticals's return on equity of -- beat Stereotaxis's return on equity of -139.2%.

Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 503.45%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 155.68%. Given that Armata Pharmaceuticals has higher upside potential than Stereotaxis, analysts believe Armata Pharmaceuticals is more attractive than Stereotaxis.

Armata Pharmaceuticals has a beta of 0.914, which suggesting that the stock is 8.595% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Stereotaxis quarterly revenues of $6.3M. Armata Pharmaceuticals's net income of $2.6M is higher than Stereotaxis's net income of -$7.5M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 420.46x versus 5.57x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.